{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:03:43Z","timestamp":1793703823830,"version":"4.5.1"},"reference-count":42,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Diputaci\u00f3 de Lleida","award":["PIRS-2024-07"],"award-info":[{"award-number":["PIRS-2024-07"]}]},{"name":"Diputaci\u00f3 de Lleida","award":["PI22\/01687"],"award-info":[{"award-number":["PI22\/01687"]}]},{"name":"Diputaci\u00f3 de Lleida","award":["2021SGR00761"],"award-info":[{"award-number":["2021SGR00761"]}]},{"name":"European Union","award":["PIRS-2024-07"],"award-info":[{"award-number":["PIRS-2024-07"]}]},{"name":"European Union","award":["PI22\/01687"],"award-info":[{"award-number":["PI22\/01687"]}]},{"name":"European Union","award":["2021SGR00761"],"award-info":[{"award-number":["2021SGR00761"]}]},{"name":"Agency for the Management of University and Research Grants","award":["PIRS-2024-07"],"award-info":[{"award-number":["PIRS-2024-07"]}]},{"name":"Agency for the Management of University and Research Grants","award":["PI22\/01687"],"award-info":[{"award-number":["PI22\/01687"]}]},{"name":"Agency for the Management of University and Research Grants","award":["2021SGR00761"],"award-info":[{"award-number":["2021SGR00761"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Recent studies have demonstrated the high analytical and diagnostic performance of plasma p-tau217 using well-defined cohorts. We aimed to assess the analytical, diagnostic, and prognostic utility of plasma p-tau217 as a routine biomarker in symptomatic patients attending our memory clinic. We also sought to identify optimal cutoff points that align with cerebrospinal fluid (CSF) amyloid beta (A\u03b2) status. A total of 276 cognitively impaired patients were included, with 81 mild cognitive impairment (MCI) patients followed for a mean of 56 (\u00b115.8) months to evaluate progression to Alzheimer\u2019s disease (AD). CSF and blood biomarkers of AD were quantified using the Lumipulse G platform. Plasma p-tau217 levels showed strong correlations with CSF A\u03b242\/A\u03b240 (r = \u22120.707), p-tau181\/A\u03b242 (r = 0.842), and p-tau181 (r = 0.728). Plasma p-tau217 levels were significantly higher in the A + T + group than in A \u2212 T +\/\u2212 (p &lt; 0.001) and outperformed other plasma markers in detecting CSF A\u03b2 pathology (AUC 0.924).Additionally, p-tau217 moderated cognitive changes over time as measured by the Mini-mental state examination (MMSE) (F(2, 70) = 13.995, p &lt; 0.001) and outperformed other plasma biomarkers in predicting progression from MCI to AD (AUC 0.876). Using a dual cutoff strategy, 72% of patients were classified with 94.9% concordance with CSF A\u03b2 status. Plasma p-tau217 shows strong potential as a non-invasive, cost-effective diagnostic and prognostic tool in clinical settings.<\/jats:p>","DOI":"10.3390\/ijms26146771","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:01:05Z","timestamp":1752591665000},"page":"6771","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-7160","authenticated-orcid":false,"given":"Farida","family":"Dakterzada","sequence":"first","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4604-7862","authenticated-orcid":false,"given":"Ricard","family":"L\u00f3pez-Ortega","sequence":"additional","affiliation":[{"name":"Laboratori Clinical ICS, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Vilella-Figuerola","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Montero-Castilla","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Riba-Llena","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ruiz-Juli\u00e1n","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Arias","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6030-3375","authenticated-orcid":false,"given":"Jordi","family":"Sarto","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Tahan","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Pi\u00f1ol-Ripoll","sequence":"additional","affiliation":[{"name":"Unitat de Trastorns Cognitius, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, 25198 Lleida, Spain"},{"name":"Unitat d\u2019Alzheimer i Altres Trastorns Cognitius, Hospital Cl\u00ednic de Barcelona\u2013Fundaci\u00f3 de Recerca Cl\u00ednic Barcelona\u2013Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (FRCB\u2013IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/mp.2017.108","article-title":"Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer\u2019s disease dementia","volume":"23","author":"Chiotis","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dakterzada, F., Cipriani, R., L\u00f3pez-Ortega, R., Arias, A., Riba-Llena, I., Ruiz-Juli\u00e1n, M., Huerto, R., Tahan, N., Matute, C., and Capetillo-Zarate, E. (2024). Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer\u2019s Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms. Int. J. Mol. Sci., 25.","DOI":"10.21203\/rs.3.rs-3887496\/v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Leuzy","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13195-023-01174-0","article-title":"The dynamics of plasma biomarkers across the Alzheimer\u2019s continuum","volume":"15","author":"Guo","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","article-title":"Comparison of ELISA- and SIMOA-based quantification of plasma A\u03b2 ratios for early detection of cerebral amyloidosis","volume":"12","author":"Schaeverbeke","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E473","DOI":"10.1212\/WNL.0000000000201479","article-title":"Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort","volume":"100","author":"Planche","year":"2023","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp-2022-330619","article-title":"Plasma biomarkers for Alzheimer\u2019s disease: A field-test in a memory clinic","volume":"94","author":"Altomare","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e055485","DOI":"10.1002\/alz.055485","article-title":"Blood phosphorylated tau 181 predicts early, preclinical brain amyloid deposition","volume":"17","author":"McGrath","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_19","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Feizpour, A., Doecke, J.D., Dor\u00e9, V., Krishnadas, N., Huang, K., Bourgeat, P., Lawsd, S.M., Fowlera, C., Robertsona, J., and Mackintosh, L. (2024). Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. eBioMedicine, 109.","DOI":"10.1016\/j.ebiom.2024.105405"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/brain\/awad042","article-title":"Predicting amyloid PET and tau PET stages with plasma biomarkers","volume":"146","author":"Jack","year":"2023","journal-title":"Brain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers","volume":"80","author":"Ashton","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","article-title":"Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort","volume":"271","author":"Mendes","year":"2024","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00415-025-12897-5","article-title":"Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer\u2019s disease diagnosis in a memory clinic cohort","volume":"272","author":"Sarto","year":"2025","journal-title":"J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","article-title":"Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease","volume":"16","author":"Arranz","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13195-024-01555-z","article-title":"Performance of plasma p-tau217 for the detection of amyloid-\u03b2 positivity in a memory clinic cohort using an electrochemiluminescence immunoassay","volume":"16","author":"Dyer","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e14502","DOI":"10.1002\/alz.14502","article-title":"Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease","volume":"21","author":"Chong","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","first-page":"e088364","article-title":"Effect of kidney function on plasma pTau217 concentrations using different pTau217 assays","volume":"20","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform","volume":"31","author":"Palmqvist","year":"2025","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1002\/alz.13804","article-title":"APOE \u03b54 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors","volume":"20","author":"Cooper","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3233\/JAD-210673","article-title":"Association of APOE \u03f54 and Plasma p-tau181 with Preclinical Alzheimer\u2019s Disease and Longitudinal Change in Hippocampus Function","volume":"85","author":"Salami","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e080482","DOI":"10.1002\/alz.080482","article-title":"The effects of ApoE e4 genotype on plasma p-tau181 concentrations on clinically diagnosed Alzheimer\u2019s disease (AD) compared to controls","volume":"19","author":"Hsiung","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/jnnp-2024-333467","article-title":"Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment","volume":"95","author":"Lehmann","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology\u2014recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Hillis","year":"2011","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6771\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:06Z","timestamp":1760033406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":42,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146771"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146771","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}